GSC Advanced Research and Reviews

eISSN: 2582-4597 CODEN (USA): GARRC2

Cross Ref DOI: 10.30574/gscarr

Journal homepage: https://gsconlinepress.com/journals/gscarr/

(REVIEW ARTICLE)

Check for updates

Nanoparticles based drug delivery system for cancer therapy

Nisha D. Masane [1,*], Arti S. Rathod [1], Vaibhav G. Akhand [2], Vinayak A. Katekar [2] and Swati P. Deshmukh [3]

[1] *Department of Pharmacy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.*
[2] *Department of Quality Assurance, Shraddha Institute of Pharmacy, Washim Maharashtra, India.*
[3] *Department of Pharmacology, Shraddha Institute of Pharmacy, Washim Maharashtra, India.*

GSC Advanced Research and Reviews, 2025, 22(01), 223-237

Publication history: Received on 02 December 2024; revised on 16 January 2025; accepted on 19 January 2025

Article DOI: https://doi.org/10.30574/gscarr.2025.22.1.0014

Abstract

Nanoparticle-based drug delivery systems (NDDS) have emerged as a transformative approach in cancer therapy, offering significant advantages over conventional treatments. This review explores the diverse applications of nanoparticles in cancer therapy, highlighting their role in enhancing drug delivery, reducing systemic toxicity, and overcoming challenges such as drug resistance and tumor heterogeneity. Nanoparticles, including liposomes, polymeric nanoparticles, metallic nanoparticles, and more recently developed systems like carbon nanotubes, dendrimers, and exosomes, are engineered for targeted drug delivery. These nanoparticles improve the pharmacokinetics and bioavailability of anticancer agents, enabling site-specific accumulation through mechanisms such as the enhanced permeability and retention (EPR) effect and active targeting via ligands. Additionally, nanoparticles play a critical role in combination therapies, immunotherapy, and overcoming multidrug resistance (MDR) by bypassing efflux pumps and targeting cancer stem cells (CSCs).

Emerging innovations in "smart" nanoparticles, capable of responding to environmental triggers like pH or temperature, as well as their integration with RNA-based therapies and artificial intelligence (AI) for personalized treatment, represent the future direction of cancer nanomedicine. Despite the progress, regulatory challenges, safety concerns, and large-scale manufacturing remain key hurdles. This review provides an overview of the current landscape, challenges, and future prospects of NDDS in cancer therapy, emphasizing their potential to improve clinical outcomes and revolutionize cancer treatment.

Keywords: Nanoparticles; Cancer therapy; Drug delivery; Multidrug resistance; Combination therapy; Personalized medicine; Immunotherapy

1. Introduction

Cancer remains one of the foremost global health challenges, consistently ranking as a leading cause of death despite remarkable advancements in its diagnosis and treatment. Traditional cancer therapies, such as chemotherapy, radiation, and surgical intervention, although widely used, have inherent limitations. These include poor targeting specificity, high systemic toxicity, limited success in treating metastatic disease, and the development of drug resistance, all of which diminish their overall effectiveness. As a result, the search for more innovative, efficient, and safer treatment modalities has intensified in recent years.

Nanotechnology has emerged as a groundbreaking approach in the fight against cancer, offering solutions to many of the obstacles faced by conventional therapies. Nanoparticle- based drug delivery systems (NDDS) are at the forefront of this innovation, capitalizing on the unique properties of materials at the nanoscale (1 to 100 nanometers). These nanoparticles can be precisely engineered to carry and deliver a wide range of therapeutic agents including

* Corresponding author: Nisha D Masane

chemotherapeutic drugs, proteins, nucleic acids, and even imaging agents directly to tumor sites while sparing healthy tissues. This specificity greatly enhances therapeutic outcomes and reduces harmful side effects.

A major advantage of NDDS is their ability to exploit the enhanced permeability and retention (EPR) effect. The abnormal, leaky blood vessels in tumors, combined with poor lymphatic drainage, allow nanoparticles to accumulate passively within tumor tissue, providing a natural targeting mechanism. Additionally, nanoparticles can be customized with specific ligands, such as antibodies, peptides, or other molecules, which enable active targeting by binding to receptors on the surface of cancer cells. This dual approach, utilizing both passive and active targeting mechanisms, significantly improves the precision of drug delivery, increasing the concentration of the therapeutic agent at the tumor site while minimizing off-target effects.

Beyond their role in improving targeted drug delivery, nanoparticles offer promising solutions to some of the most pressing challenges in oncology. One of these is multidrug resistance (MDR), a condition in which cancer cells develop mechanisms to counteract the effects of chemotherapeutic agents, rendering traditional treatments less effective. Nanoparticles can be designed to bypass or overcome these resistance mechanisms, enabling drugs to retain their efficacy. Furthermore, nanoparticles provide a versatile platform for combination therapies, allowing the co-delivery of multiple therapeutic agents within a single particle. This can be particularly beneficial in cancer therapy, as different agents can simultaneously attack cancer cells through various pathways, reducing the likelihood of resistance development and enhancing overall treatment efficacy.

This comprehensive review examines the diverse types of nanoparticles that have been developed for cancer therapy. Liposomes, polymeric nanoparticles, metallic nanoparticles, and emerging systems like carbon nanotubes, dendrimers, and quantum dots are just some of the many nanoparticle platforms currently being investigated. Each of these systems offers unique advantages in terms of drug loading capacity, stability, biocompatibility, and functionalization potential. Additionally, the role of nanoparticles in enhancing immunotherapy—an area of growing importance in cancer treatment—is discussed, as these tiny carriers can be engineered to modulate the immune system, improve the delivery of immunotherapeutic agents, and even act as adjuvants to stimulate a stronger anti-tumor immune response.

Personalized cancer treatment is another area where nanoparticle-based systems show great promise. Nanoparticles can be tailored to an individual's unique tumor characteristics, allowing for highly customized therapies that align with the principles of precision medicine. This ability to deliver treatment that is specifically designed for a patient's cancer subtype holds significant potential for improving outcomes and reducing unwanted side effects.

Despite their numerous advantages, the clinical translation of nanoparticle-based therapies is not without challenges. Regulatory hurdles, potential long-term safety concerns, and the complexity of large-scale manufacturing remain significant barriers that must be addressed. However, ongoing research in nanotechnology is rapidly advancing, with efforts focused on improving nanoparticle design, optimizing therapeutic efficacy, and ensuring safety.

In summary, nanotechnology offers a transformative approach to cancer treatment, with nanoparticle-based systems representing a versatile and highly effective strategy for overcoming the limitations of conventional therapies. As research continues to evolve, the future of cancer therapy is likely to become increasingly personalized, targeted, and effective, driven by the continued integration of nanoparticles into clinical practice.

TYPES OF NANOPARTICLES USED IN CANCER THERAPY Nanoparticle-based drug delivery systems have become a revolutionary approach in cancer treatment, offering enhanced drug bioavailability, targeted delivery, and reduced side effects. Different types of nanoparticles have been developed, each with unique properties that can be

tailored for specific cancer therapies. The major types of nanoparticles used in cancer therapy include liposomes, polymeric nanoparticles, metallic nanoparticles, dendrimers, carbon nanotubes, and exosomes.[1]

1.1. Liposomes

Liposomes are spherical vesicles consisting of one or more phospholipid bilayers, which can encapsulate both hydrophilic and hydrophobic drugs. Liposomes have been widely used in cancer therapy due to their biocompatibility, ability to encapsulate a wide range of drugs, and their potential for passive tumor targeting through the enhanced permeability and retention (EPR) effect. The surface of liposomes can be modified with polyethylene glycol (PEG) to increase circulation time or with ligands for active targeting.[2]

One of the earliest FDA-approved liposomal formulations is Doxil®, a PEGylated liposomal doxorubicin, which has been used in the treatment of various cancers, including ovarian cancer and Kaposi's sarcoma. The PEGylation of liposomes reduces their recognition by the immune system, enhancing drug accumulation at the tumor site. [1,3]

1.2. Polymeric Nanoparticles

Polymeric nanoparticles are formed from biodegradable polymers such as poly(lactic-co- glycolic acid) (PLGA), polycaprolactone (PCL), and chitosan. These nanoparticles can be tailored for controlled drug release, offering sustained drug delivery over extended periods. Polymeric nanoparticles are versatile, enabling encapsulation of drugs, proteins, or nucleic acids, and can also be surface-modified for targeted delivery. [1,2]

PLGA-based nanoparticles have been extensively studied for their ability to encapsulate chemotherapeutic agents and provide sustained release. They have shown promising results in enhancing drug bioavailability and minimizing side effects. For example, PLGA nanoparticles encapsulating paclitaxel have been developed to improve the efficacy and reduce the toxicity of this chemotherapeutic agent. [2,3]

1.3. Metallic Nanoparticles

Metallic nanoparticles, such as gold, silver, and iron oxide nanoparticles, offer unique properties, including easy surface modification, optical properties, and magnetic responsiveness. Gold nanoparticles (AuNPs) are particularly useful in cancer therapy due to their biocompatibility and ability to absorb and scatter light, making them suitable for photothermal therapy (PTT) and imaging applications.[1]

Gold nanoparticles can be used to enhance the effect of radiation therapy or combined with photothermal agents to induce localized heating and destroy cancer cells. Iron oxide nanoparticles are primarily used in magnetic hyperthermia and as contrast agents for magnetic resonance imaging (MRI), helping in both the diagnosis and treatment of cancers. [1,2]

1.4. Dendrimers

Dendrimers are highly branched, tree-like synthetic polymers that can be used as carriers for drug molecules. Their well-defined structure, multivalency, and internal cavities make them suitable for encapsulating a wide range of therapeutic agents, including drugs, genes, and imaging agents. Dendrimers offer the advantage of targeted delivery, as their surface can be functionalized with targeting ligands, and their size can be precisely controlled.

Dendrimer-based drug delivery systems have shown promise in delivering chemotherapeutic agents, such as doxorubicin, with enhanced targeting to cancer cells while minimizing systemic toxicity. Additionally, dendrimers can be used for the co-delivery of drugs and genes, enabling combination therapies that target multiple pathways involved in cancer progression. [1,3]

1.5. Carbon Nanotubes (CNTs)

Carbon nanotubes (CNTs) are cylindrical nanostructures composed of graphene sheets rolled into a tube-like shape. They possess unique mechanical, electrical, and thermal properties, making them attractive for drug delivery, imaging, and photothermal therapy. CNTs can be functionalized with targeting ligands and used to deliver chemotherapeutic agents directly to cancer cells.

CNTs also play a role in cancer imaging and therapy through photothermal therapy [PTT), where they absorb near-infrared light and convert it into heat, destroying cancer cells. Their ability to deliver drugs while simultaneously facilitating thermal ablation of tumors has made them a promising platform for multimodal cancer therapy.[1,3]

1.6. Exosomes

Exosomes are naturally occurring extracellular vesicles, approximately 30–150 nm in size, secreted by various cells. These vesicles play a key role in intercellular communication and can carry proteins, lipids, and nucleic acids. Recently, exosomes have gained attention as drug delivery systems due to their biocompatibility, ability to cross biological barriers, and low immunogenicity. [3,4]

In cancer therapy, exosomes can be engineered to deliver chemotherapeutic agents, nucleic acids (such as siRNA or miRNA), and even immunomodulatory molecules. Exosome-based drug delivery systems are still in the early stages of

development, but they hold potential for delivering personalized cancer treatments due to their natural targeting capabilities.[1,2,3]

1.7. Mesoporous Silica Nanoparticles (MSNs)

Mesoporous silica nanoparticles (MSNs) are a class of inorganic nanoparticles characterized by their high surface area, large pore volume, and tunable pore sizes. MSNs can encapsulate various drugs within their porous structure and release them in response to specific stimuli, such as pH or temperature. The surface of MSNs can be functionalized with targeting ligands to enhance drug delivery specificity.[3,2]

MSNs have been studied for their ability to deliver chemotherapeutic agents like doxorubicin, paclitaxel, and cisplatin. They have demonstrated potential in achieving controlled drug release, improving therapeutic efficacy, and reducing side effects in cancer treatment.[1,4]

2. Mechanisms of nanoparticle-based drug delivery in cancer therapy

Nanoparticles (NPs) offer several distinct mechanisms for drug delivery, which can enhance the therapeutic index of anticancer agents by improving targeting, reducing off-target effects, and ensuring controlled drug release. These mechanisms typically involve passive and active targeting strategies that exploit the unique physiological characteristics of tumors or involve surface modification for more precise delivery.[5,6]

2.1. Passive Targeting via the Enhanced Permeability and Retention (EPR) Effect

One of the primary mechanisms for nanoparticle-based drug delivery is passive targeting, which exploits the enhanced permeability and retention (EPR) effect. Tumors, especially solid tumors, exhibit leaky vasculature with large endothelial gaps due to rapid and abnormal angiogenesis, resulting in enhanced permeability. Additionally, poor lymphatic drainage in tumors allows nanoparticles to accumulate and retain within the tumor microenvironment for prolonged periods.[5,7]

Nanoparticles in the size range of 10–100 nm can take advantage of the EPR effect by entering the tumor through these leaky vasculatures and accumulating due to poor drainage. This passive targeting enhances the concentration of the therapeutic agent at the tumor site while reducing exposure to healthy tissues, minimizing systemic toxicity.[8]

Despite the potential of the EPR effect, it can be variable across different tumor types and among individual patients due to the heterogeneity of tumor vasculature. To improve the efficacy of passive targeting, researchers have been developing stimuli-responsive nanoparticles that release their payload in response to the tumor's unique environment (e.g., pH, hypoxia, or enzymes).[1,5]

2.2. Active Targeting via Ligand-Modified Nanoparticles

While passive targeting takes advantage of the unique physiological features of tumors, such as their leaky vasculature and poor lymphatic drainage, active targeting adds a more specific layer of precision. In active targeting, nanoparticles are modified with ligands, peptides, or antibodies that have a high affinity for particular receptors that are often overexpressed on the surface of cancer cells. This method not only enhances the selectivity of the drug delivery system but also ensures that the therapeutic agents are delivered more efficiently to the cancer cells, increasing the likelihood of internalization and improving the therapeutic outcome by minimizing off-target effects and reducing harm to healthy tissues.. [7,8]

2.3. Ligands commonly used for active targeting include:

- Antibodies or antibody fragments: Monoclonal antibodies targeting specific tumor- associated antigens (e.g., HER2 for breast cancer) can be attached to nanoparticles, improving the binding specificity to cancer cells.
- Peptides: Short peptide sequences (e.g., RGD peptides targeting integrins) can be conjugated to nanoparticles, targeting proteins that are overexpressed in tumors.
- Folate: Folate receptors are overexpressed in various cancers. Nanoparticles conjugated with folic acid or folate derivatives can selectively target these cancers.
- Aptamers: Aptamers are short, single-stranded DNA or RNA molecules that can bind to specific proteins with high affinity. Nanoparticles functionalized with aptamers can be used to target tumor markers.

Active targeting allows for more precise delivery of drugs to cancer cells, increasing the therapeutic efficacy and reducing side effects.[5,8]

2.4. Controlled Drug Release

One of the key advantages of nanoparticle-based drug delivery systems is their ability to provide controlled drug release. Controlled release refers to the ability of nanoparticles to release their therapeutic payload in a regulated manner over time, ensuring sustained drug concentrations at the tumor site. This can be achieved through various mechanisms, such as:

- pH-Sensitive Nanoparticles: Tumors often have a more acidic environment compared to normal tissues. pH-sensitive nanoparticles are designed to remain stable in the neutral pH of blood but release their drug cargo in the acidic tumor microenvironment. This selective release helps to maximize drug efficacy and minimize off-target effects.[1,8]
- Thermo-Responsive Nanoparticles: These nanoparticles are engineered to release their payload in response to increased temperatures, such as those induced by external stimuli (e.g., hyperthermia therapy). Tumor tissues can be heated to trigger drug release from nanoparticles.[5,6]
- Redox-Sensitive Nanoparticles: Tumor cells often exhibit higher levels of reactive oxygen species (ROS) and a more reducing environment than normal cells. Redox-sensitive nanoparticles can degrade and release their cargo in response to the high redox potential of cancer cells.[5]

2.5. Cellular Uptake of Nanoparticles

Once nanoparticles reach the tumor site, they must be taken up by cancer cells to deliver their therapeutic payload. Nanoparticles can enter cells through various endocytic pathways, such as clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis. The route of cellular uptake depends on the size, shape, surface charge, and composition of the nanoparticle[2,8].

After internalization, nanoparticles are often trafficked to the endo-lysosomal pathway, where acidic conditions or enzymatic degradation can trigger drug release. To enhance the cytoplasmic release of the drug, researchers have developed nanoparticles that can escape from endosomes before degradation. This “endosomal escape” is a key factor in ensuring that the drug reaches its intracellular targets.[5,6]

2.6. Nanoparticles in Tumor Penetration

Efficient drug penetration throughout the tumor mass is crucial for effective cancer therapy. However, the dense extracellular matrix (ECM) of tumors and poor perfusion make it difficult for drugs to penetrate deep into the tumor. Nanoparticles can be designed to enhance tumor penetration in several ways:

- Multistage Nanoparticles: These nanoparticles are engineered to change their size or surface properties after reaching the tumor, allowing them to penetrate deeper into the tumor mass. For example, large nanoparticles can shrink into smaller ones once inside the tumor, improving diffusion through the ECM.[6,7]
- Enzyme-Responsive Nanoparticles: Certain nanoparticles are designed to release enzymes such as collagenase that degrade the ECM, allowing better penetration of the drug into the tumor core.[6,8]

3. Delivery systems in cancer therapy

Nanoparticles (NPs) have been extensively researched and applied in various facets of cancer treatment, offering innovations in chemotherapy, radiation therapy, photothermal therapy (PTT), and immunotherapy. Their versatility in drug delivery, ability to carry multiple therapeutic agents, and potential for tumor-specific targeting make them highly suitable for overcoming the limitations of traditional cancer treatments. This section discusses key applications of NP-based drug delivery systems in cancer therapy.[9,10]

3.1. Chemotherapy

Conventional chemotherapy is often associated with systemic toxicity, poor bioavailability, and the inability to differentiate between healthy and cancerous cells. Nanoparticle-based systems address these limitations by enhancing the delivery of chemotherapeutic agents directly to tumor sites, thus reducing off-target toxicity and improving the therapeutic index.[11,13]

3.2. Drug Encapsulation

Nanoparticles can encapsulate various chemotherapeutic drugs, such as paclitaxel, doxorubicin, cisplatin, and docetaxel, protecting the drug from premature degradation and improving its bioavailability. By encapsulating drugs, nanoparticles can enhance their solubility and stability in the bloodstream, prolonging circulation times. For example, Doxil®, a PEGylated liposomal formulation of doxorubicin, has demonstrated improved efficacy and reduced cardiotoxicity compared to free doxorubicin [12].

3.3. Combination Therapy

Nanoparticles can also deliver multiple drugs simultaneously, enabling combination therapies that attack cancer through different pathways. For instance, polymeric nanoparticles have been developed to co-deliver paclitaxel and cisplatin, two chemotherapeutic agents with complementary mechanisms of action. This co-delivery strategy ensures that both drugs are delivered to the tumor in the correct ratio, increasing therapeutic synergy while reducing systemic side effects. [1,13]

3.4. Radiation Therapy

Radiation therapy (RT) is a common cancer treatment, but it often leads to collateral damage to healthy tissues surrounding the tumor. Nanoparticle-based systems have shown potential in enhancing the efficacy of RT while minimizing damage to normal tissues.[2]

3.5. Radiosensitizers

Nanoparticles can be designed as radiosensitizers, enhancing the sensitivity of tumor cells to radiation. Metallic nanoparticles, particularly gold nanoparticles (AuNPs), have shown great promise in this application due to their ability to enhance the local radiation dose absorbed by the tumor. The high atomic number of gold allows AuNPs to absorb X-rays more efficiently, generating reactive oxygen species [ROS) and amplifying radiation-induced DNA damage in cancer cells. Gold nanoparticles conjugated with targeting ligands can be selectively accumulated in tumor tissues, further improving the specificity of radiation therapy.[12]

3.6. Combination of NP-Mediated RT and Chemotherapy

Nanoparticles can also be used to combine radiation therapy with chemotherapy, delivering both a radio sensitizer and a chemotherapeutic agent in one platform. For example, studies have shown that platinum-based chemotherapeutic drugs, such as cisplatin, can act as radio sensitizers. By encapsulating cisplatin in nanoparticles, it is possible to deliver the drug and enhance radiation therapy simultaneously, improving the overall treatment efficacy. [13,14]

3.7. Photothermal Therapy (PTT)

Photothermal therapy (PTT) uses nanoparticles that absorb near-infrared (NIR) light and convert it into heat, selectively destroying cancer cells through hyperthermia. Metallic nanoparticles, such as gold nanorods, gold nanoshells, and carbon nanotubes, are ideal candidates for PTT because of their strong optical absorption properties in the NIR region, where biological tissues exhibit minimal absorption. [11,13]

3.8. Gold Nanoparticles in PTT

Gold nanoparticles are widely used in PTT due to their biocompatibility and ability to absorb NIR light. When irradiated with NIR light, gold nanoparticles generate heat that can induce thermal ablation of cancer cells. By modifying the surface of gold nanoparticles with targeting ligands, they can be directed specifically to tumors, reducing damage to surrounding healthy tissues. AuroLase®, a gold nanoshell-based system, has been developed for use in PTT and is currently in clinical trials for treating prostate and other cancers. [12,14]

3.9. Carbon Nanotubes in PTT

Carbon nanotubes (CNTs) are another class of nanoparticles that exhibit excellent NIR absorption and photothermal conversion efficiency. Functionalized CNTs can deliver drugs or be used in combination with PTT for dual therapy. Upon exposure to NIR light, CNTs generate localized heat, destroying cancer cells without the need for high systemic doses of chemotherapeutic agents.[13]

3.10. Immunotherapy

Immunotherapy, which harnesses the body's immune system to fight cancer, has shown remarkable promise in cancer treatment. Nanoparticles can be engineered to enhance the delivery of immunotherapeutic agents, such as immune checkpoint inhibitors, cytokines, or vaccines, to improve the efficacy of immunotherapy.[11]

3.11. Delivery of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have revolutionized cancer therapy. However, their systemic administration can lead to immune- related adverse effects. Nanoparticles can be designed to deliver checkpoint inhibitors directly to the tumor microenvironment, improving efficacy while reducing off-target effects. For instance, lipid nanoparticles loaded with anti-PD-L1 antibodies have been developed to enhance the delivery of checkpoint inhibitors, leading to greater tumor regression in preclinical studies. [12,14]

3.12. Cancer Vaccines

Nanoparticles are also being investigated as delivery vehicles for cancer vaccines, which stimulate the immune system to recognize and attack cancer cells. Nanoparticles can protect antigens from degradation and enhance their uptake by dendritic cells, improving the immune response. Liposome-based cancer vaccines have shown promise in delivering tumor- associated antigens to immune cells, stimulating a stronger and more specific anti-tumor immune response.[13,11]

3.13. Gene Therapy

Nanoparticles offer a versatile and efficient platform for delivering nucleic acids, including small interfering RNA (siRNA), microRNA (miRNA), and plasmid DNA (pDNA), which are used to regulate or modulate gene expression in cancer cells, potentially silencing oncogenes or restoring the function of tumor suppressor genes. These nanoparticles not only protect the fragile nucleic acids from degradation by enzymes in the bloodstream but also enhance their cellular uptake by facilitating transport across cellular membranes, ensuring they reach the target cells and achieve the desired therapeutic effects within the intracellular environment.[11,13]

3.14. Small interfering RNA (siRNA) Delivery

Silencing specific genes involved in cancer progression, such as oncogenes or drug resistance genes, is an attractive therapeutic approach. Nanoparticles can encapsulate siRNA molecules, protecting them from nucleases and ensuring efficient cellular uptake. Lipid nanoparticles are commonly used for siRNA delivery, and Patisiran, an FDA-approved lipid nanoparticle-based siRNA drug, demonstrates the potential of this technology. [11,12]

3.15. CRISPR-Cas9 Delivery

The CRISPR-Cas9 gene-editing system offers precise genome modification, making it a powerful tool for correcting genetic mutations associated with cancer. Nanoparticles can deliver the CRISPR-Cas9 components (e.g., Cas9 protein and guide RNA) directly to cancer cells, enabling targeted gene editing. Polymeric nanoparticles have been successfully used to deliver CRISPR-Cas9 components for in vivo gene editing, showing promise for future cancer therapies.[12]

4. Challenges and limitations of nanoparticle-based drug delivery systems in cancer therapy

Despite the promise and potential of nanoparticles (NPs) in cancer therapy, their clinical translation faces several challenges. Understanding these limitations is critical for improving current nanoparticle-based strategies and developing next-generation nanomedicines. This section outlines some key challenges related to their design, pharmacokinetics, manufacturing, and regulatory hurdles. [13,14,15]

4.1. Complexity of Nanoparticle Design and Fabrication

One of the major challenges in developing effective nanoparticle-based drug delivery systems is the complexity of their design and fabrication. NPs must be carefully engineered to achieve the desired size, shape, surface properties, and drug-loading capacity. Each modification can influence the particle's biodistribution, clearance, and therapeutic efficacy. [14,15]

4.2. Size and Shape Optimization

The size and shape of nanoparticles play a critical role in their biological behavior, including circulation time, tumor penetration, and cellular uptake. However, optimizing these parameters for different types of cancers is challenging. For instance, smaller nanoparticles (<100 nm) penetrate tumors more easily but are cleared quickly by the kidneys, while larger nanoparticles (>200 nm) have longer circulation times but may struggle to penetrate deeply into tumors. Achieving an optimal balance between these factors remains difficult. (13]

4.3. Surface Functionalization and Stability

Nanoparticles need to be surface-functionalized with ligands or stabilizing agents such as polyethylene glycol (PEG) to improve targeting and prolong circulation times. However, functionalization can introduce immunogenicity or reduce the stability of the nanoparticles in biological environments, leading to premature drug release or aggregation. PEGylation, for example, can sometimes trigger immune reactions (the "PEG dilemma"), limiting the nanoparticle's effectiveness.[15]

4.4. Biological Barriers and Biodistribution

After systemic administration, nanoparticles encounter several biological barriers that impede their delivery to the tumor site, including protein adsorption, immune system recognition, and rapid clearance by the liver and kidneys.[14]

4.5. Protein Corona Formation

Once in the bloodstream, nanoparticles are rapidly coated by proteins, forming a protein corona. This corona alters the particle's surface properties, affecting its recognition by immune cells, circulation time, and uptake by cancer cells. The protein corona can cause nanoparticles to be recognized as foreign bodies by the immune system, leading to their clearance from the bloodstream. [16,14]

4.6. Clearance by the Mononuclear Phagocyte System (MPS)

Nanoparticles are often recognized by the mononuclear phagocyte system (MPS), which includes macrophages in the liver and spleen. As a result, a large proportion of injected nanoparticles are sequestered by these organs, significantly reducing the amount that reaches the tumor. Strategies such as PEGylation, discussed earlier, can help reduce MPS uptake, but overcoming this challenge entirely is still a major obstacle.[15]

4.7. Limited Tumor Penetration

While nanoparticles can passively accumulate in tumors via the enhanced permeability and retention (EPR) effect, they often have difficulty penetrating deep into the tumor tissue. The dense extracellular matrix (ECM) and abnormal vasculature in tumors impede nanoparticle diffusion, limiting their effectiveness. Furthermore, the EPR effect is highly variable across different tumor types and stages, reducing the consistency of NP delivery in clinical settings.[14]

4.8. Drug Loading Efficiency and Controlled Release

Nanoparticles must be able to carry sufficient quantities of therapeutic agents to achieve the desired therapeutic effect. However, the drug loading capacity of nanoparticles is often limited by their size and composition. Moreover, ensuring controlled and sustained drug release at the tumor site is another challenge. [15,16]

4.9. Limited Drug Loading Capacity

The amount of drug that can be loaded into or onto nanoparticles is often constrained by their small size. High drug loading can lead to aggregation or destabilization of the nanoparticles, while low drug loading may result in suboptimal therapeutic outcomes. Researchers are exploring different strategies, such as core-shell structures and polymeric matrices, to improve drug-loading efficiency. [15,16]

4.10. Premature Drug Release

Uncontrolled or premature drug release can occur during circulation, leading to toxicity and reduced efficacy. Ensuring that nanoparticles release their drug payload only in response to specific stimuli (such as pH, temperature, or enzymes) at the tumor site is critical, but achieving reliable control over this process is technically challenging. [15,16]

4.11. Immunogenicity and Toxicity

The safety of nanoparticle-based systems is a major concern, particularly with regard to their immunogenicity, toxicity, and long-term biocompatibility. Although nanoparticles are designed to improve drug delivery, they may induce unwanted immune responses or cause harm to healthy tissues. [14,15]

4.12. Immunogenicity

Some nanoparticles, especially those that are non-degradable or made from synthetic materials, can be recognized by the immune system as foreign particles, leading to immune activation. This can result in inflammation, hypersensitivity reactions, or even anaphylaxis. PEGylated nanoparticles, for instance, have been associated with immune reactions in some patients.[15]

4.13. Toxicity of Nanomaterials

Certain nanoparticles, particularly those made from heavy metals (e.g., gold, silver, or quantum dots), may accumulate in organs such as the liver, kidneys, and spleen, potentially causing long-term toxicity. Even biodegradable nanoparticles, such as those made from polymers, can sometimes generate toxic degradation products that pose safety risks. Comprehensive toxicity studies are required for any nanoparticle-based formulation before it can be approved for clinical use.[16]

4.14. Manufacturing and Scalability

The scalable manufacturing of nanoparticles with consistent quality, reproducibility, and stability is another significant challenge, as the intricate processes involved in nanoparticle synthesis, such as precise control over particle size, shape, and surface properties, are difficult to replicate on a large scale. The complex synthesis methods required for many nanoparticle formulations make it difficult to produce them at large scales while maintaining batch-to- batch uniformity, which is crucial to ensure that each batch has the same therapeutic efficacy and safety profile, minimizing variability in clinical outcomes. [14,15]

4.15. Reproducibility and Batch-to-Batch Variability

Small changes in nanoparticle synthesis conditions (e.g., temperature, solvent, or reactant concentrations) can lead to significant differences in size, surface properties, and drug- loading capacity. This variability can affect the nanoparticles' pharmacokinetics and therapeutic efficacy, complicating the regulatory approval process. [13,16]

4.16. Cost and Feasibility of Large-Scale Production

The high cost of raw materials and the complexity of nanoparticle manufacturing processes make it challenging to produce nanoparticle-based therapies at a cost-effective scale. For widespread clinical use, nanoparticles must be produced in large quantities while maintaining strict quality control, which remains an ongoing challenge for the nanomedicine industry. [14)

4.17. Regulatory and Clinical Approval

Obtaining regulatory approval for nanoparticle-based therapies is a complex and time- consuming process. Regulatory agencies, such as the FDA and EMA, require extensive safety and efficacy data for any new therapy, and the unique properties of nanoparticles pose additional hurdles.[16]

4.18. Regulatory Challenges

Because nanoparticles differ significantly from conventional drugs in terms of their size, structure, and behavior in the body, regulatory agencies must establish new guidelines for evaluating their safety, efficacy, and manufacturing quality. There is currently a lack of standardized protocols for assessing nanoparticle-based formulations, which complicates the approval process.[14]

4.19. Clinical Translation

Despite the large number of nanoparticle-based therapies under investigation, relatively few have successfully reached the clinic. Challenges such as the complexity of nanoparticle design, variability in biological performance, and difficulty in scaling up production contribute to the slow pace of clinical translation. Ensuring that nanoparticle-based therapies demonstrate significant clinical benefit over existing treatments is essential for gaining regulatory approval and achieving widespread clinical adoption.[14,15]

5. Regulatory perspectives and clinical translation of nanoparticle-based drug delivery systems

The transition from laboratory research to clinical application of nanoparticle-based drug delivery systems involves navigating complex regulatory pathways to ensure safety, efficacy, and quality. Understanding the regulatory landscape is crucial for researchers, developers, and clinicians aiming to bring innovative nanoparticle-based therapies to market [17][18].

5.1. Regulatory Frameworks for Nanomedicine

Regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global entities have established guidelines for evaluating the safety and efficacy of nanoparticle-based drug delivery systems. These regulations aim to address the unique challenges posed by nanomedicines, including their size, composition, and behavior in biological systems [19][20].

5.2. Risk Assessment and Safety Evaluation

Risk assessment for nanoparticle-based drugs focuses on their potential toxicity, immunogenicity, and environmental impact. Regulatory agencies require comprehensive preclinical studies that include in vitro and in vivo assessments of the nanoparticles' safety profile, biodistribution, pharmacokinetics, and potential adverse effects. Studies should also consider long-term exposure and accumulation in tissues [20][21].

5.3. Quality Control and Manufacturing Standards

Manufacturing standards for nanoparticles must ensure batch-to-batch consistency and quality. Regulatory guidelines emphasize the importance of standardizing synthesis methods, purification processes, and characterization techniques. Parameters such as size distribution, surface charge, drug loading capacity, and stability must be rigorously tested to ensure reliable performance in clinical applications [18][21].

5.4. Clinical Trials and Approval Pathways

The approval process for nanoparticle-based therapies typically follows a phased clinical trial approach, similar to conventional drug development, which includes preclinical studies, followed by Phase I, II, and III trials to evaluate safety, efficacy, and dosage. However, the complexity of nanoparticle formulations necessitates careful planning and drug release mechanisms can significantly influence the therapeutic outcome and potential side effects, requiring additional scrutiny by regulatory agencies. [22].

5.5. Phased Clinical Trials

Clinical trials for nanoparticle-based therapies generally consist of three phases:

- Phase I: Focuses on evaluating the safety, tolerability, and pharmacokinetics of the nanoparticle formulation in a small group of patients.
- Phase II: Assesses the therapeutic efficacy and optimal dosing of the nanoparticle-based therapy in a larger cohort of patients with specific cancer types.
- Phase III: Compares the nanoparticle therapy against standard treatments in a randomized, controlled trial to establish its effectiveness and safety [23].

5.6. Adaptive Trial Designs

Given the variability in patient responses to nanoparticle-based therapies, adaptive trial designs are becoming increasingly popular. These designs allow for modifications to the trial protocol based on interim results, enabling more flexible and efficient testing of nanoparticle formulations. Adaptive designs can facilitate faster identification of effective treatments and minimize patient exposure to ineffective therapies [24].

5.7. Post-Market Surveillance and Real-World Evidence

Once approved, continuous monitoring of nanoparticle-based therapies through post-market surveillance is crucial to ensure long-term safety and efficacy. Collecting real-world evidence can provide valuable insights into how these therapies perform in diverse patient populations and under varying clinical conditions [25].

5.8. Real-World Evidence Generation

Real-world evidence, derived from electronic health records, patient registries, and observational studies, can complement data from clinical trials by providing insights into treatment outcomes, adverse events, and patient-reported experiences. This information can inform clinical practice guidelines and help refine future nanoparticle-based therapies [26].

5.9. Pharmacovigilance and Risk Management

Regulatory agencies require ongoing pharmacovigilance for approved nanomedicines to monitor their safety profiles post-approval. Risk management plans should be in place to address potential adverse effects and ensure patient safety. Reporting systems for adverse events related to nanoparticle therapies should be robust and transparent, allowing for timely action when safety concerns arise [27].

6. Patient perspectives and ethical considerations in nanoparticle-based cancer therapies

As the field of nanoparticle-based drug delivery systems for cancer therapy continues to expand, it is crucial to address the perspectives of patients and the ethical considerations surrounding these innovative treatments. Understanding patient needs, concerns, and experiences can significantly impact the acceptance and effectiveness of these therapies [28][29].

6.1. Patient Awareness and Education

Patient education plays a vital role in the successful implementation of nanoparticle-based therapies. Patients must understand the nature of these treatments, how they differ from conventional therapies, and their potential benefits and risks [30].

6.2. Enhancing Patient Knowledge

Effective communication between healthcare providers and patients can help demystify nanoparticle-based therapies. Healthcare professionals should provide clear, accessible information about how these treatments work, their mechanisms of action, and expected outcomes. Educational materials, such as brochures and online resources, can aid in disseminating this information [31].

6.3. Informed Consent

Obtaining informed consent is critical in clinical settings. Patients should be adequately informed about the risks, benefits, and uncertainties associated with nanoparticle-based therapies before participating in clinical trials or receiving treatments. This process includes discussing potential side effects, the experimental nature of some therapies, and the long-term effects that are still being studied [32].

6.4. Ethical Considerations in Nanomedicine

The introduction of nanomedicine, particularly in cancer therapy, raises several ethical questions that must be addressed to ensure responsible research and clinical practices [33].

6.5. Equity in Access to Treatment

As nanoparticle-based therapies are developed, it is essential to consider issues of access and equity. These therapies may require advanced technology and expertise, potentially leading to disparities in treatment availability among different populations. Ensuring equitable access to these innovative treatments is a pressing ethical concern that must be addressed by policymakers and healthcare providers [34].

6.6. Long-Term Effects and Unknown Risks

While nanoparticles have shown promise in improving drug delivery and reducing side effects, their long-term effects on human health remain largely unknown. The ethical principle of “do no harm” necessitates thorough research into the safety and potential adverse effects of these therapies before they are widely adopted. Ongoing monitoring and research into long-term outcomes are essential to mitigate risks [35].

6.7. Environmental Impact

The production and disposal of nanoparticle-based therapies also raise environmental concerns. The potential toxicity of nanoparticles in the environment, their accumulation in ecosystems, and their long-term effects on biodiversity warrant careful consideration. Developing sustainable manufacturing processes and disposal methods is essential to minimize environmental impact [36]

7. Challenges and limitations in clinical implementation

Despite the promise of nanoparticle-based drug delivery systems, several challenges and limitations must be addressed to facilitate their successful clinical implementation [4144].

7.1. Heterogeneity in Tumor Microenvironments

Cancer heterogeneity poses a significant challenge to the effectiveness of nanoparticle-based therapies. Tumors often exhibit varied cellular characteristics, microenvironment conditions, and drug resistance mechanisms. This heterogeneity can lead to inconsistent drug distribution and limited therapeutic efficacy, making it difficult to achieve uniform treatment outcomes across different patients [37][38].

7.2. Toxicity and Biocompatibility Issues

While nanoparticles offer targeted drug delivery, concerns about their potential toxicity and biocompatibility remain. The long-term effects of nanoparticle accumulation in the body are still not fully understood. Issues such as immunogenicity, inflammatory responses, and organ- specific toxicity require ongoing research to ensure patient safety [39][40].

7.3. Scalability and Manufacturing Challenges

The transition from laboratory-scale production to commercial-scale manufacturing of nanoparticles presents unique challenges. Maintaining consistency and quality across large batches is crucial for regulatory approval and market success. Developing scalable and reproducible manufacturing processes is essential to meet the increasing demand for nanoparticle-based therapies [41][42].

7.4. Regulatory and Approval Hurdles

Navigating the regulatory landscape for nanoparticle-based therapies can be complex, as these therapies differ from traditional drugs in both their structure and behavior in biological systems. The unique characteristics of nanoparticles necessitate thorough evaluations of their safety and efficacy, requiring developers to conduct additional studies to assess parameters such as particle size, surface charge, and biodistribution. As regulatory agencies develop guidelines, staying compliant while innovating remains a significant challenge for developers, who must balance meeting evolving regulations with advancing novel therapies through the pipeline without delays. [42].

8. Conclusion

In conclusion, nanoparticle-based drug delivery systems represent a transformative advancement in cancer therapy, addressing many of the limitations associated with conventional treatments such as chemotherapy, radiotherapy, and surgery. By facilitating targeted delivery of therapeutic agents directly to tumor cells, these systems reduce damage to healthy tissues and minimize systemic toxicity, significantly improving patient outcomes. Nanoparticles allow for controlled and sustained drug release, enhancing the bioavailability of drugs and ensuring that they remain active at the tumor site for longer periods.

Furthermore, nanoparticles can exploit both passive targeting, through mechanisms like the enhanced permeability and retention (EPR) effect, and active targeting, via surface modification with ligands or antibodies that bind to specific cancer cell receptors. This dual- targeting ability maximizes treatment precision, making it possible to deliver drugs more effectively to tumor cells while sparing normal cells. Nanoparticles are also pivotal in overcoming drug resistance, a major challenge in cancer therapy, by bypassing cellular mechanisms that cancer cells use to evade chemotherapy. In addition, the ability of nanoparticles to deliver multiple drugs simultaneously allows for combination therapies, which can target cancer through different biological pathways, enhancing therapeutic efficacy and reducing the likelihood of resistance development.

Despite these advancements, there remain significant challenges related to the clinical translation of nanoparticle-based therapies, particularly in terms of regulatory approvals, long-term safety, and large-scale manufacturing. However, ongoing research is rapidly advancing the field, addressing these concerns while continuously improving the design, functionality, and application of nanoparticles. As personalized medicine gains traction, nanoparticles offer an exceptional platform for tailoring cancer treatments to individual patients, paving the way for more effective, less toxic, and highly targeted therapies. Overall, the integration of nanotechnology into oncology holds great promise for revolutionizing cancer treatment and improving survival rates worldwide.

Compliance with ethical standards

Disclosure of conflict of interest

Sincere gratitude is extended by the writers to the management for providing the facilities needed to finish the work References.

References

[1] Zhao, Y., Zeng, Y., & Li, Y. (2014). Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomaterials Science, 2(5), 690-702.

[2] Vangijzegem, T., Stanicki, D., & Laurent, S. (2020). Magnetic nanoparticle-based hyperthermia for cancer therapy. Progress in Nanomedicine, 37(3), 71-82.

[3] Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117-134.

[4] Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance, 2(2), 141-160.

[5] Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135–146.

[6] Cai, W., Gao, T., Hong, H., & Sun, J. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology Science and Applications, 1(1), 17-32.

[7] Chen, Q., Xu, L., & Liu, Z. (2020). Nanoparticle-mediated targeted drug delivery systems for precision cancer therapy. Signal Transduction and Targeted Therapy, 5, 193.

[8] Sharma, T., Jain, A., Kaur, R., Saini, S., Katare, O., & Singh, B. (2020). Supersaturated LFCS type III self-emulsifying delivery systems of sorafenib tosylate with improved biopharmaceutical performance: QbD-enabled development and evaluation. Drug Delivery and Translational Research, 10(3), 839-861.

[9] Hammami, I., Alabdallah, N. M., & Kamoun, M. (2021). Gold nanoparticle-based drug nanocarriers as a targeted drug delivery system platform for cancer therapeutics. Journal of King Saud University – Science, 33(1), 1-10.

[10] Zhang, J., Wang, S., He, X., & Han, H. (2023). Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Frontiers in Immunology, 14, 1230893.

[11] Yao, Y., Zhou, Y., & Liu, L. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences, 7, 193.

[12] Libutti, S. K., Paciotti, G. F., & Byrnes, A. A. (2010). Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clinical Cancer Research, 16(21), 6139–6149. https://doi.org/10.1158/1078-0432.CCR-10-0978

[13] Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215-223.

[14] Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer, 5(3), 161-171.

[15] Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 83(5), 761-769.

[16] Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric-Bernstam, F., & Ferrari, M. (2011). Nanomedicine in cancer therapy: innovative trends and future perspectives. Nanomedicine, 6(5), 754-764.

[17] Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013). The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine, 9(1), 1-14.

[18] Lim, M., Park, J., Shin, S. W., Lee, W., & Moon, J. H. (2018). Regulatory considerations and challenges in nanomedicine. Journal of Pharmaceutical Sciences, 107(5), 1247-1254.

[19] Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33(10), 2373-2387.

[20] Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20.

[21] Sun, Y., & Xia, T. (2016). Nanomaterial-based drug delivery approaches in cancer therapy. Nanomedicine: Nanotechnology, Biology and Medicine, 11(3), 1819-1834.

[22] Akhter, S., Ahmad, Z., & Ahmad, M. (2018). Emerging applications of nanomedicines in cancer therapy. Drug Development and Industrial Pharmacy, 44(8), 1295-1308.

[23] Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505-515.

[24] Amreddy, N., Babu, A., Muralidharan, R., Munshi, A., & Ramesh, R. (2018). Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Materials Science and Engineering: C, 89, 108-119.

[25] Aryal, S., Hu, C. M. J., & Zhang, L. (2011). Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Molecular Pharmaceutics, 8(4), 1401-1407.

[26] Bao, G., Mitragotri, S., & Tong, S. (2013). Multifunctional nanoparticles for cancer therapy. Annual Review of Biomedical Engineering, 15, 253-282.

[27] Cabral, H., & Kataoka, K. (2014). Progress of drug-loaded polymeric micelles into clinical studies. Journal of Controlled Release, 190, 465-476.

[28] Chen, Y., & Gao, Y. (2017). Nanoparticle-based photodynamic therapy for cancer treatment. Cancer Biology & Medicine, 14(2), 134-141.

[29] Colombo, M., Fiandra, L., Mazzucchelli, S., Truffi, M., Sorrentino, L., Corsi, F., & Prosperi, D. (2016). Tumor targeting by nanoparticles: alternatives to passive and active targeting. ACS Nano, 10(8), 775-782.

[30] Davis, M. E., Chen, Z. G., & Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), 771-782.

[31] Duncan, R., & Gaspar, R. (2011). Nanomedicine(s) under the microscope. Molecular Pharmaceutics, 8(6), 2101-2141.

[32] Gao, H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B, 6(4), 268-286.

[33] Hrkach, J., Von Hoff, D., Mukkar, H., & Farokhzad, O. C. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), 128ra39.

[34] Jain, R. K., & Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 7(11), 653-664.

[35] Khan, M. I., Mohammad, A., Patil, G., Naqvi, S. A., & Chauhan, L. K. S. (2017). Nanoparticles: properties, applications, and toxicities. Arabian Journal of Chemistry, 12(7), 908-931.

[36] Maeda, H. (2012). Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proceedings of the Japan Academy, Series B, 88(3), 53-71.

[37] Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013). Nanomedicine therapeutic approaches to overcome cancer drug resistance. Advanced Drug Delivery Reviews, 65(13-14), 1866-1879.

[38] Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.

[39] Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010). Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Letters, 10(9), 3223-3230.

[40] Suh, J., & Han, H. S. (2015). Stimuli-sensitive nanoparticles for cancer treatment. Biomaterials Science, 3(9), 1170-1176.

[41] Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1(5), 1- 12.

[42] Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.